FINKE, Juergen, Claudia SCHMOOR, Wolfgang A. BETHGE, Hellmut D. OTTINGER, Matthias STELLJES, Axel R. ZANDER, Liisa VOLIN, Dominik A. HEIM, Rainer SCHWERDTFEGER, Karin KOLBE, Jiří MAYER, Johan A. MAERTENS, Werner LINKESCH, Ernst HOLLER, Vladimír KOZA, Martin BORNHAEUSER, Hermann EINSELE, Hartmut BERTZ, Olga GRISHINA and Gerard SOCIE. Prognostic Factors Affecting Outcome after Allogeneic Transplantation for Hematological Malignancies from Unrelated Donors: Results from a Randomized Trial. Biology of Blood and Marrow Transplantation. New York, USA: ELSEVIER SCIENCE, 2012, vol. 18, No 11, p. 1716-1726. ISSN 1083-8791. doi:10.1016/j.bbmt.2012.06.001.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Prognostic Factors Affecting Outcome after Allogeneic Transplantation for Hematological Malignancies from Unrelated Donors: Results from a Randomized Trial
Authors FINKE, Juergen (276 Germany, guarantor), Claudia SCHMOOR (276 Germany), Wolfgang A. BETHGE (276 Germany), Hellmut D. OTTINGER (276 Germany), Matthias STELLJES (276 Germany), Axel R. ZANDER (276 Germany), Liisa VOLIN (246 Finland), Dominik A. HEIM (756 Switzerland), Rainer SCHWERDTFEGER (276 Germany), Karin KOLBE (276 Germany), Jiří MAYER (203 Czech Republic, belonging to the institution), Johan A. MAERTENS (56 Belgium), Werner LINKESCH (40 Austria), Ernst HOLLER (276 Germany), Vladimír KOZA (203 Czech Republic), Martin BORNHAEUSER (276 Germany), Hermann EINSELE (276 Germany), Hartmut BERTZ (276 Germany), Olga GRISHINA (276 Germany) and Gerard SOCIE (250 France).
Edition Biology of Blood and Marrow Transplantation, New York, USA, ELSEVIER SCIENCE, 2012, 1083-8791.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30200 3.2 Clinical medicine
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 3.940
RIV identification code RIV/00216224:14110/12:00063576
Organization unit Faculty of Medicine
UT WoS 000310493700013
Keywords in English Allogeneic hematopoietic stem-cell transplantation; Graft-versus-host-disease prophylaxis; HLA-matching
Tags International impact, Reviewed
Changed by Changed by: Ing. Mgr. Věra Pospíšilíková, učo 9005. Changed: 7. 2. 2013 11:45.
Several prognostic factors for the outcome after allogeneic hematopoietic stem-cell transplant (HSCT) from matched unrelated donors have been postulated from registry data; however, data from randomized trials are lacking. We present analyses on the effects of patient-related, donor-related, and treatment-related prognostic factors on acute GVHD (aGVHD), chronic GVHD (cGVHD), relapse, nonrelapse mortality (NRM), disease-free survival (DFS), and overall survival (OS) in a randomized, multicenter, open-label, phase III trial comparing standard graft-versus-host-disease (GVHD) prophylaxis with and without pretransplantation ATG-Fresenius (ATG-F) in 201 adult patients receiving myeloablative conditioning before HSCT from HLA-A, HLA-B antigen, HLA-DRBI, HLA-DQBI allele matched unrelated donors. High-resolution testing (allele) of HLA-A, HLA-B, and HLA-C were obtained after study closure, and the impact of an HLA 10/10 4-digit mismatch on outcome and on the treatment effect of ATG-F versus control investigated. Advanced disease was a negative factor for relapse, DFS, and OS. Donor age >= 40 adversely affected the risk of aGVHD III-IV, extensive cGVHD, and OS. Younger donors are to be preferred in unrelated donor transplantation. Advanced disease patients need special precautions to improve outcome. The degree of mismatch had no major influence on the positive effect of ATG-F on the reduction of aGVHD and cGVHD.
PrintDisplayed: 26. 6. 2022 11:03